85607-79-0

Upstream product

• 28478-45-7 methyl 4-benzyloxy-2-methoxybenzoate 
• 5427-29-2 methyl 2-hydroxy-4-benzyloxybenzoate 
• 100-44-7 benzyl chloride 
• 719274-37-0 4-Benzyloxy-2-methoxy-benzonitrile 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 58026-14-5 4-(benzyloxy)-2-methoxybenzaldehyde 
• 100-39-0 benzyl bromide 

Downstream Products

• 95420-58-9 2-(4-Benzyloxy-2-methoxy-phenyl)-3H-imidazo[4,5-c]pyridine 
• 5448-45-3 4-(benzyloxy)-2-hydroxybenzoic acid 
• 86315-65-3 2-(4-hydroxy-2-methoxyphenyl)imidazo(4,5-c)pyridine 
• 924642-69-3 (4-benzyloxy-2-methoxy-phenyl)-(4-methyl-piperazin-1-yl)-methanone 
• 107238-24-4 2-Methoxy-4-benzyloxybenzoyl chloride 
• 99446-17-0 8-(2-methoxy-4-benzyloxy-phenyl)-2-chloro-purine 
• 90111-34-5 4-hydroxy-2-methoxybenzoic acid 

Relevant academic research and scientific papers

COMPOUNDS AND THEIR USES AS MIF INHIBITORS

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the i

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

Synthesis of p-O-Alkyl Salicylanilide Derivatives as Novel EGFR Inhibitors

(Table Presented) Epidermal growth factor receptor (EGFR), a validated target for anticancer drugs, plays a critical role in tumorigenesis and tumor development. A series of p-O-alkyl salicylanilide derivatives were designed and synthesized as novel EGFR inhibitors using a salicylic acid scaffold. A simulated six-membered ring strategy formed through intramolecular hydrogen bonds was employed to mimic the planar quinazoline of the EGFR antagonist, gefitinib. The derived compounds with hydroxyl at the ortho position were more potent than ones with methoxyl group. In particular, compounds 5d and 5b displayed significant EGFR inhibitory (IC50 values = 0.30 and 0.45 μM, respectively) activity as well as potent antiproliferative activity in A431 and HCT-116 tumor cells. These salicylanilides could be considered as promising lead compounds for developing novel EGFR inhibitors.

HETEROCYCLIC AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS

A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.

N-(3-pyrrolidinyl) benzamide derivative

N-(3-Pyrrodinyl)benzamide derivatives represented by the following general formula (I) which have potent and selective antagonism against dopamine D3 and/or D4 receptor and are useful as a psychotropic, a schizophrenia-treating agent and the like, or a pharmaceutically acceptable salt thereof or a pharmaceutical preparation thereof. STR1

Selective endothelin A receptor ligands. 1. Discovery and structure-activity of 2,4-disubstituted benzoic acid derivatives

This paper describes the discovery of a new non-peptide endothelin A (ET(A)) selective ligand, 2,4-dibenzyloxybenzoic acid 3, which inhibits the binding of [125I]ET-1 to ET(A) receptors with an IC50 of 9 μM (ET-1 = endothelin-1). Optimisation of 3 resulted in compound 52 which had an IC50 of 1 μM. One of the analogues of 3, compound 15, was examined in a functional assay and shown to antagonise ET-1-induced contraction of rat aorta. The identification of 3 was made through the application of ChemDBS-3D searching of our corporate database. The 3D query, using an aromatic ring to a carboxylic acid group separated by 10.2 ± 1.1 A, was derived from an examination of common pharmacophoric distances found in the low energy conformations of two known ET(A) antagonists, the cyclic pentapeptide BQ 123 1 and myriceron caffeoyl ester 2.